Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Effects of FX006 on Blood Glucose in Patients With OA of the Knee and Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Willingness and ability to comply with the study procedures and visit schedules and ability to follow verbal and written instructions~* Male or female ≥40 years of age~* Type 2 diabetes mellitus for at least 1 year prior to Screening and not managed with injectable agents (e.g. insulin or insulin analogs, exenatide, pramlintide, liraglutide)~* Currently treated with 1 or 2 oral agents for diabetes, with stable doses for at least 2 months~* HbA1c ≥6.5% and ≤ 9.0%~* Currently meets American College of Rheumatology (ACR) Criteria (clinical or radiological) for OA.~* Symptoms associated with OA of the knee for ≥ 6 months prior to Screening~* Index knee pain on most days (\>15) over the last month (as reported by the patient)~* Body mass index (BMI) ≤ 40 kg/m2~* Willingness to abstain from use of protocol-specified restricted medications during the study~* Willingness to wear a CGM device uninterrupted for 24 hours per day throughout the study, remain with receiving range and comply with calibration requirements~* Accustomed to using a Standard Blood Glucose Measuring device by finger stick~Exclusion Criteria:~* Reiter's syndrome, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis or arthritis associated with inflammatory bowel disease~* History of infection in the index knee joint~* Clinical signs and symptoms of active knee infection or crystal disease of the index knee within 1 month of Screening~* Presence of surgical hardware or other foreign body in the index knee~* Unstable joint (such as a torn anterior cruciate ligament) within 12 months of screening~* IA corticosteroid (investigational or marketed) in any joint within 3 months of Screening~* IA hyaluronic acid (investigational or marketed) in the index knee within 6 months of Screening~* IV or intramuscular (IM) corticosteroids (investigational or marketed) within 3 months of Screening~* Oral corticosteroids (investigational or marketed) within 1 month of Screening~* Inhaled, intranasal or topical corticosteroids (investigational or marketed) within 2 weeks of Screening~* Any other IA investigational drug/biologic within 6 months of Screening~* Prior use of FX006~* Use of acetaminophen, or acetaminophen containing products~* Current use of a continuous glucose monitoring device~* Women of child-bearing potential not using effective contraception or who are pregnant or nursing

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FX006 32 mg (Type: EXPERIMENTAL): Single 5 mL intra-articular (IA) injection Extended-release Formulation
- TCA IR 40 mg (Type: ACTIVE_COMPARATOR): Single 1 mL intra-articular (IA) injection Immediate-release Formulation

Based on this trial design, predict the completion outcome and termination type (if applicable).